Sept 14 Impax Laboratories Inc and
Israel's Teva Pharmaceutical Industries Ltd settled a
two-year patent dispute with Johnson & Johnson, allowing
the generic drugmakers to start selling a copy of Johnson &
Johnson's ADHD drug from July 14, 2013.
In 2010, J&J unit Alza filed a lawsuit to block Impax from
launching a copy of Alza's Concerta extended-release tablets
that treat attention deficit hyperactivity disorder.
According to Wolters Kluwer Health, U.S. brand and generic
sales of Concerta were about $1.2 billion for the 12 months
ended July 2012, Impax said in a statement.
The Concerta products are part of Impax's 2001 strategic
alliance agreement with Teva. Teva has already filed with U.S.
regulators to get approval for a generic version of the drug.
Under the settlement, Alza has agreed to give Impax and Teva
a license to sell generic versions of Concerta on July 14, 2013,
or earlier under certain circumstances, Impax said.